CRDF Cardiff Oncology, Inc.
NEUTRAL
Impact: 4/10
PRESS-RELEASE
Press release: fda
Latest settled — T+5d
CRDF ▼ -16.85% at T+5d
NEUTRAL call ✗ call lost -16.85% · α vs SPY -18.51% · entry $1.78 → $1.48
Currently $1.46 · -17.98% from $1.78 entry
T+1d
+8.99%
call +8.99% · α +8.40%
$1.94
settled 19d ago
T+5d
-16.85%
call -16.85% · α -18.51%
$1.48
settled 12d ago
T+20d
—
call — · α —
—
in 12d
T+60d
—
call — · α —
—
in 2mo
Price Chart
Loading chart...
Executive Summary
Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC at ASCO on June 2, 2026, followed by an investor webcast on June 3. No actual results were released today, making this a routine catalyst-date announcement.
Actionable Insight
Traders should monitor ASCO data release on June 2; positive results could drive significant upside given the $126M market cap and high unmet need, while negative data poses substantial downside risk. No action warranted until data is released.
Key Facts
- Updated data from the Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC will be presented at ASCO on June 2, 2026.
- An investor webcast is scheduled for June 3, 2026 to review the data.
- Previous data showed dose-dependent improvements in overall response rate and progression-free survival.
- The company has selected the 30 mg dose for a registrational trial.
Financial Impact
Not specified
Risk Factors
- Updated data may fail to meet prior expectations or show safety concerns.
- Historical performance shows high-scoring bullish calls on CRDF have underperformed at T+20, suggesting caution on pre-data optimism.
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299771 |
10 reports for CRDF
63%
Hit rate
best @ T+1▲ +10.71%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
7d ago
|
8-K
| $1.40 $1.55 | ▲ +10.71% | ▲ +10.32% | $1.46 (+4.29%) |
|
Jun 2, 2026
8d ago
|
Press Release
| $1.51 $1.40 | ▼ −7.28% | ▼ −6.59% | $1.46 (−3.31%) |
|
May 29, 2026
11d ago
|
8-K
| $1.48 $1.51 | ▼ −2.03% | ▼ −1.88% | $1.46 (+1.35%) |
|
May 21, 2026
19d ago
|
Press Release
| $1.78 $1.94 | ▲ +8.99% | ▲ +8.40% | $1.46 (−17.98%) |
|
May 19, 2026
21d ago
|
8-K
| $1.84 $1.79 | ▲ +2.72% | ▲ +2.91% | $1.46 (+20.65%) |
|
May 14, 2026
26d ago
|
8-K
| $1.67 $1.69 | ▲ +1.20% | ▲ +1.26% | $1.46 (−12.57%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $1.78 $1.65 | ▼ −7.30% | ▼ −6.65% | $1.46 (−17.98%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $1.82 $1.80 | ▼ −1.10% | ▲ +0.64% | $1.46 (−19.78%) |
|
Feb 25, 2026
15w ago
|
8-K
| $1.91 $1.96 | ▲ +2.62% | ▲ +3.16% | $1.46 (−23.56%) |
|
Feb 24, 2026
15w ago
|
8-K
| $1.91 $1.96 | ▲ +2.62% | ▲ +3.16% | $1.46 (−23.56%) |
Showing 10 of 10
US Market Status
Market Open — Closes in 1h 17m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access